Literature DB >> 11389122

Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.

L Saravolatz1, O Manzor, C Check, J Pawlak, B Belian.   

Abstract

The in vitro and pharmacodynamic effects of moxifloxacin and gatifloxacin against Streptococcus pneumoniae were compared with six other fluoroquinolones. Organisms included penicillin-susceptible (54) and penicillin-non-susceptible (145) isolates from 1998-1999. Moxifloxacin and clinafloxacin demonstrated the greatest in vitro activity, with MIC90s of 0.13 mg/L, followed by trovafloxacin, grepafloxacin > gatifloxacin, sparfloxacin > levofloxacin > ciprofloxacin. There was no difference in fluoroquinolone activity between penicillin-susceptible and -non-susceptible strains. Pharmacodynamic analysis using published pharmacokinetic information indicates that all the agents tested except ciprofloxacin had an AUC/MIC90 > 30, with moxifloxacin having the greatest free-drug availability.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389122     DOI: 10.1093/jac/47.6.875

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.

Authors:  Kristina Öbrink-Hansen; Tore Forsingdal Hardlei; Birgitte Brock; Søren Jensen-Fangel; Marianne Kragh Thomsen; Eskild Petersen; Mads Kreilgaard
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

Review 2.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.

Authors:  Yoshiko Otsu; Katsunori Yanagihara; Yuichi Fukuda; Yoshitsugu Miyazaki; Kazuhiro Tsukamoto; Yoichi Hirakata; Kazunori Tomono; Jun-ichi Kadota; Takayoshi Tashiro; Ikuo Murata; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

4.  Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany.

Authors:  H Koch; H Landen; K Stauch
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

5.  Biochemical Characterization of New Gemifloxacin Schiff Base (GMFX-o-phdn) Metal Complexes and Evaluation of Their Antimicrobial Activity against Some Phyto- or Human Pathogens.

Authors:  Hazem S Elshafie; Sadeek A Sadeek; Ippolito Camele; Amira A Mohamed
Journal:  Int J Mol Sci       Date:  2022-02-14       Impact factor: 5.923

Review 6.  Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.

Authors:  Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.